12:00 AM
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ALX-0651: Development discontinued

Ablynx discontinued development of ALX-0651 as part of its pipeline prioritization. The company said preliminary data from a single-blind, placebo-controlled, Dutch Phase I...

Read the full 94 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >